CDK4 and cancer: Theoretically, it would be predicted that many human cancers will show increased CDK4/6 reliance and make ideal candidates for CDK4/6 inhibitor treatment since they often activate CDK4/6 genes or have transcriptional aberrations through a variety of mechanisms [5,6].